Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a randomized controlled trial.

Their objective was to study the association between serum levels of anti Epstein-Barr virus nuclear antigen 1 (EBNA-1) antibody and 25-hydroxyvitamin D (25(OH)D) in a prospective cohort of patients with relapsing-remitting multiple sclerosis.

Who Took Part

The abstract describes 90 patients taking part.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.

The study comprised 90 patients with relapsing-remitting multiple sclerosis, all participants in a randomized clinical trial of ω-3 fatty acids (the OFAMS study).

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The association between serum EBNA-1 IgG and serum 25(OH)D levels was analysed using generalized linear models for hierarchical data.

What Was Measured

Topics PubMed links to this paper include Epstein-Barr Virus Nuclear Antigens, HLA-DRB1 Chains, Multiple Sclerosis and Vitamin D.

The authors tagged it with the keywords prospective cohort study.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 90 patients in people with multiple sclerosis.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (European journal of neurology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.